Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Personalized Medicine Middle: Coalition Sends Consensus Concepts To Hill

This article was originally published in The Gray Sheet

Executive Summary

What can diagnostic firms, drug companies, physicians, insurers, researcher centers and patient advocacy groups all agree on when it comes to policies to support personalized medicine?

You may also be interested in...



FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail

FDA's draft guidance on the development of companion diagnostics for drug therapies, released July 12, delivers on a promise to publicly outline how it will address review of those products, but at only 12 pages, it has left some in industry longing for more insight.

AdvaMedDx Steps Into Public Sphere: Director Details Diagnostics Priorities

The recently established diagnostics arm of AdvaMed had what its executive director called a coming out party last week.

Personalized Medicine Coalition Renews Pitch For Modern Coding System

Medicare coding is outdated and too general for today’s molecular diagnostics. And the resulting uncertainty about how to code and adequately pay for the next-generation tests hampers investment and innovation in the field, according to a lobbying paper released Dec. 7 by the Personalized Medicine Coalition.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT030468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel